However, we report similar treatment discontinuation rates due to any grade toxicity in BRAF/MEK-treated patients in daily clinical practice compared to trial patients (33% versus 26% in the COMBI-AD trial) [1]. The gene discussed is BRAF; the disease is Alzheimer disease.